Highnoon Laboratories Limited
PPSX:HINOON921.27
PKR
-9.64
(-1.04%)
ISIN
PK0070701013
Return %
Stock
S&P 500
1Y
-19.66
14.20
3Y
121.86
81.12
5Y
98.67
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Adeel Abbas Haideri
- Full Time Employees
- 2,563
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Lahore Pakistan
- IPO Date
- Jan 16, 1995
- Website
- highnoon-labs.com
- Similar Companies
- Business
- Highnoon Laboratories Limited is a Pakistan-based pharmaceutical and healthcare company engaged in the research, development, manufacturing, marketing, and distribution of prescription pharmaceuticals, nutraceuticals, consumer health products, and therapeutic formulations. Founded in 1984 and headquartered in Lahore, Pakistan, the company operates across major therapeutic segments, offering cardiovascular therapies, including antihypertensives, beta-blockers, and lipid-lowering agents such as Combivasc, Lipirex, and K-Vas; alimentary tract and metabolic treatments, including anti-ulcerants, gastroprokinetics, and appetite stimulants such as Ulsanic and Tres-Orix Forte; endocrinology and antidiabetic medicines, including dipeptidyl peptidase-4 inhibitors and biguanide combinations such as Tagip and Tagip-Met; respiratory care treatments, including antiasthmatics, antihistamines, and expectorants such as Pulmonol, Cast-NF, and Brofex; anti-infective medications, including cephalosporin and macrolide antibiotics such as Ceftron and Zithrox; central nervous system formulations for psychiatric and neurological disorders; musculoskeletal and analgesic therapies for acute and chronic pain management; and nutritional supplements, pediatric multivitamins, and calcium formulations such as Qalsan. The company operates cGMP-compliant manufacturing facilities in Lahore and supplies its portfolio to retail pharmacies, private clinics, healthcare institutions, and government hospitals throughout Pakistan, while exporting finished pharmaceutical goods to international markets across Central Asia, the Middle East, Africa, and South Asia. Highnoon Laboratories operates a wholly owned subsidiary, Route2Health (Private) Limited, which oversees the commercialization, retail store operations, and e-commerce distribution of premium wellness supplements, vitamins, and natural wellness brands. In recent operational developments, the company has expanded its manufacturing infrastructure through investments in automated solid dosage and sterile production lines to align with stringent international regulatory standards; introduced new oral antidiabetic and cardioprotective fixed-dose combination formulations to treat chronic metabolic conditions; accelerated international regulatory filings and product registrations in emerging export markets; and scaled the distribution footprint of its consumer healthcare and nutraceutical division across modern retail and digital channels.